These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37481263)

  • 1. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
    Cersosimo E; Alatrach M; Solis-Herrera C; Baskoy G; Adams J; Hansis-Diarte A; Gastaldelli A; Chavez A; Triplitt C; DeFronzo RA
    J Clin Endocrinol Metab; 2023 Dec; 109(1):161-170. PubMed ID: 37481263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
    Alatrach M; Agyin C; Solis-Herrera C; Lavryneko O; Adams J; Gastaldelli A; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes Care; 2022 Jun; 45(6):1372-1380. PubMed ID: 35235659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
    Solis-Herrera C; Daniele G; Alatrach M; Agyin C; Triplitt C; Adams J; Patel R; Gastaldelli A; Honka H; Chen X; Abdul-Ghani M; Cersosimo E; Del Prato S; DeFronzo R
    Diabetes Care; 2020 May; 43(5):1065-1069. PubMed ID: 32144165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
    Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
    Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.
    Harreiter J; Just I; Leutner M; Bastian M; Brath H; Schelkshorn C; Klepochova R; Krššák M; Kautzky-Willer A
    Diabetes Obes Metab; 2021 May; 23(5):1129-1139. PubMed ID: 33464703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
    Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
    Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
    Camastra S; Astiarraga B; Tura A; Frascerra S; Ciociaro D; Mari A; Gastaldelli A; Ferrannini E
    Diabetes Obes Metab; 2017 Mar; 19(3):412-420. PubMed ID: 27898183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.
    Pereira MJ; Lundkvist P; Kamble PG; Lau J; Martins JG; Sjöström CD; Schnecke V; Walentinsson A; Johnsson E; Eriksson JW
    Diabetes Ther; 2018 Aug; 9(4):1511-1532. PubMed ID: 29949016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
    Gastaldelli A; Balas B; Ratner R; Rosenstock J; Charbonnel B; Bolli GB; Boldrin M; Balena R
    Diabetes Obes Metab; 2014 Feb; 16(2):170-8. PubMed ID: 23911196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects.
    Chen X; Tripathy D; Chilton R; Hansis-Diarte A; Salehi M; Solis-Herrera C; Cersosimo E; DeFronzo RA
    Diabetes; 2024 Jun; 73(6):896-902. PubMed ID: 38512770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
    Kim YJ; Hwang SD; Lim S
    Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
    Solis-Herrera C; Triplitt C; Garduno-Garcia Jde J; Adams J; DeFronzo RA; Cersosimo E
    Diabetes Care; 2013 Sep; 36(9):2756-62. PubMed ID: 23579178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
    Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
    Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
    Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.